PortfoliosLab logo
ELV vs. ABBV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ELV and ABBV is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

ELV vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Elevance Health Inc (ELV) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

ELV:

-0.87

ABBV:

0.71

Sortino Ratio

ELV:

-1.08

ABBV:

0.97

Omega Ratio

ELV:

0.86

ABBV:

1.15

Calmar Ratio

ELV:

-0.68

ABBV:

0.85

Martin Ratio

ELV:

-1.13

ABBV:

2.09

Ulcer Index

ELV:

20.84%

ABBV:

8.49%

Daily Std Dev

ELV:

27.49%

ABBV:

27.46%

Max Drawdown

ELV:

-67.19%

ABBV:

-45.09%

Current Drawdown

ELV:

-27.23%

ABBV:

-14.01%

Fundamentals

Market Cap

ELV:

$93.17B

ABBV:

$328.29B

EPS

ELV:

$25.69

ABBV:

$2.34

PE Ratio

ELV:

15.75

ABBV:

78.89

PEG Ratio

ELV:

0.74

ABBV:

0.39

PS Ratio

ELV:

0.51

ABBV:

5.72

PB Ratio

ELV:

2.19

ABBV:

229.63

Total Revenue (TTM)

ELV:

$183.12B

ABBV:

$57.37B

Gross Profit (TTM)

ELV:

$114.62B

ABBV:

$44.44B

EBITDA (TTM)

ELV:

$10.09B

ABBV:

$16.33B

Returns By Period

In the year-to-date period, ELV achieves a 10.13% return, which is significantly higher than ABBV's 5.83% return. Over the past 10 years, ELV has underperformed ABBV with an annualized return of 11.34%, while ABBV has yielded a comparatively higher 15.72% annualized return.


ELV

YTD

10.13%

1M

-7.29%

6M

-3.47%

1Y

-23.88%

5Y*

9.63%

10Y*

11.34%

ABBV

YTD

5.83%

1M

6.95%

6M

-5.73%

1Y

19.02%

5Y*

20.92%

10Y*

15.72%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Elevance Health Inc

AbbVie Inc.

Risk-Adjusted Performance

ELV vs. ABBV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELV
The Risk-Adjusted Performance Rank of ELV is 1313
Overall Rank
The Sharpe Ratio Rank of ELV is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of ELV is 1212
Sortino Ratio Rank
The Omega Ratio Rank of ELV is 1212
Omega Ratio Rank
The Calmar Ratio Rank of ELV is 1010
Calmar Ratio Rank
The Martin Ratio Rank of ELV is 2222
Martin Ratio Rank

ABBV
The Risk-Adjusted Performance Rank of ABBV is 7373
Overall Rank
The Sharpe Ratio Rank of ABBV is 7777
Sharpe Ratio Rank
The Sortino Ratio Rank of ABBV is 6565
Sortino Ratio Rank
The Omega Ratio Rank of ABBV is 6868
Omega Ratio Rank
The Calmar Ratio Rank of ABBV is 8181
Calmar Ratio Rank
The Martin Ratio Rank of ABBV is 7474
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ELV vs. ABBV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Elevance Health Inc (ELV) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ELV Sharpe Ratio is -0.87, which is lower than the ABBV Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of ELV and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

ELV vs. ABBV - Dividend Comparison

ELV's dividend yield for the trailing twelve months is around 1.63%, less than ABBV's 3.46% yield.


TTM20242023202220212020201920182017201620152014
ELV
Elevance Health Inc
1.63%1.77%1.26%1.00%0.98%1.18%1.06%1.14%1.20%1.81%1.79%1.39%
ABBV
AbbVie Inc.
3.46%3.49%3.82%3.49%3.84%4.41%4.83%3.89%2.65%3.64%3.41%2.54%

Drawdowns

ELV vs. ABBV - Drawdown Comparison

The maximum ELV drawdown since its inception was -67.19%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for ELV and ABBV. For additional features, visit the drawdowns tool.


Loading data...

Volatility

ELV vs. ABBV - Volatility Comparison

The current volatility for Elevance Health Inc (ELV) is 8.07%, while AbbVie Inc. (ABBV) has a volatility of 9.90%. This indicates that ELV experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

ELV vs. ABBV - Financials Comparison

This section allows you to compare key financial metrics between Elevance Health Inc and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B20.00B30.00B40.00B50.00B20212022202320242025
48.89B
13.34B
(ELV) Total Revenue
(ABBV) Total Revenue
Values in USD except per share items

ELV vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between Elevance Health Inc and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20212022202320242025
89.8%
83.9%
(ELV) Gross Margin
(ABBV) Gross Margin
ELV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Elevance Health Inc reported a gross profit of 43.91B and revenue of 48.89B. Therefore, the gross margin over that period was 89.8%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a gross profit of 11.20B and revenue of 13.34B. Therefore, the gross margin over that period was 83.9%.

ELV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Elevance Health Inc reported an operating income of 3.14B and revenue of 48.89B, resulting in an operating margin of 6.4%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported an operating income of 3.73B and revenue of 13.34B, resulting in an operating margin of 28.0%.

ELV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Elevance Health Inc reported a net income of 2.18B and revenue of 48.89B, resulting in a net margin of 4.5%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a net income of 1.29B and revenue of 13.34B, resulting in a net margin of 9.6%.


ELV vs. ABBV - Valuation Comparison

The chart below illustrates the valuation comparison between Elevance Health Inc and AbbVie Inc. over time, highlighting four key metrics: Price-to-Earnings (P/E) Ratio, Price/Earnings to Growth (PEG) Ratio, Price-to-Sales (P/S) Ratio, and Price-to-Book (P/B) Ratio.

ELV - PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ELV, comparing it with other companies in the Healthcare Plans industry. Currently, ELV has a P/E ratio of 15.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

ABBV - PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ABBV, comparing it with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/E ratio of 78.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

ELV - PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ELV compared to other companies in the Healthcare Plans industry. ELV currently has a PEG ratio of 0.7. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

ABBV - PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ABBV compared to other companies in the Drug Manufacturers - General industry. ABBV currently has a PEG ratio of 0.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

ELV - PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ELV relative to other companies in the Healthcare Plans industry. Currently, ELV has a P/S ratio of 0.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

ABBV - PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ABBV relative to other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/S ratio of 5.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

ELV - PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ELV in comparison with other companies in the Healthcare Plans industry. Currently, ELV has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

ABBV - PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ABBV in comparison with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/B value of 229.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

User Portfolios with ELV or ABBV


challenge
29%
YTD
META
MSFT
LLY
III.L
NVDA
GOOGL
RTX
HWM
PLTR
RHM.DE
MSTR
BABA
FTNT
AVGO
AON
ABBV
AAS.L
ADMA
AMZN
STRL
ICE
LMB
LRN
MP
ACHR
V
HOOD
NWG.L
UL
RYCEY
CELH
CCEP.L
MELI
BP
ckbest2-1
26%
YTD
ABBV
IBM
MMM
BRK-B
WM
COST
JPM
RNMBY
GE
PGR
GILD
TGTX
1 / 90

Recent discussions